Last reviewed · How we verify

NCT05254977

Post Vaccination Adverse Events in Covid-19 Vaccine Recipients

Completed Last updated 13 April 2022
What this trial tests

trial testing Standard Preparation in COVID-19 Vaccination in 3,515 participants. Completed in 30 March 2022.

Timeline
26 February 2022
Primary endpoint
10 March 2022
30 March 2022

Quick facts

Lead sponsorIslamia University of Bahawalpur
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,515
Start date26 February 2022
Primary completion10 March 2022
Estimated completion30 March 2022
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Islamia University of Bahawalpur

Who can join

12 and older, any sex, with COVID-19 Vaccination or Vaccine Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Covid-19 pandemic is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-Cov-2) since its outbreak 2019. Protection against Covid-19 can be achieved through global immunization. Various vaccines for SARS-Cov-2 has been registered and approved for administration in humans. It is important to understand the safety and efficacy of vaccines during robust research to develop global immunity against SARS-Cov-2. This study aimed to collect data on post vaccination adverse events in regional population of District Bahawalpur.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Standard Preparation

Trials testing the same drug.

Other recruiting trials for COVID-19 Vaccination

Currently open trials in the same condition.

Other Islamia University of Bahawalpur trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05254977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing